Similar articles

• Personalized neoantigen vaccines: A new approach to cancer immunotherapy.

  Aldous AR, Dong JZ. Aldous AR, et al. Bioorg Med Chem. 2018 Jun 1;26(10):2842-2849. doi: 10.1016/j.bmc.2017.10.021. Epub 2017 Oct 19. Bioorg Med Chem. 2018. PMID: 29111369 Review.
• Therapeutic cancer vaccines: From initial findings to prospects.

  Song Q, Zhang CD, Wu XH. Song Q, et al. Immunol Lett. 2018 Apr;196:11-21. doi: 10.1016/j.imlet.2018.01.011. Epub 2018 Feb 4. Immunol Lett. 2018. PMID: 29407608 Review.
• Personalized cancer vaccines: adjuvants are important, too.

  Gouttefangeas C, Rammensee HG. Gouttefangeas C, et al. Cancer Immunol Immunother. 2018 Dec;67(12):1911-1918. doi: 10.1007/s00262-018-2158-4. Epub 2018 Apr 11. Cancer Immunol Immunother. 2018. PMID: 29644387 Free PMC article. Review.
• Editorial: Approaches to Advance Cancer Vaccines to Clinical Utility.

  Van Nuffel AMT, Boudousquié C, Tuyaerts S. Van Nuffel AMT, et al. Front Immunol. 2019 Aug 27;10:2032. doi: 10.3389/fimmu.2019.02032. eCollection 2019. Front Immunol. 2019. PMID: 31507617 Free PMC article. No abstract available.
• Cancer-testis antigens: targets for cancer immunotherapy.

  Chen YT, Old LJ. Chen YT, et al. Cancer J Sci Am. 1999 Jan-Feb;5(1):16-7. Cancer J Sci Am. 1999. PMID: 10188055 Review. No abstract available.